Back to Browse Journals » Patient Related Outcome Measures » Volume 2

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival

Authors Falanga A, Vignoli A, Diani E, Marchetti M

Published Date November 2011 Volume 2011:2 Pages 175—188

DOI http://dx.doi.org/10.2147/PROM.S10099

Published 23 November 2011

Anna Falanga, Alfonso Vignoli, Erika Diani, Marina Marchetti
Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy

Abstract: Patients with cancer are at high risk of developing venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism. Compared to non-cancer patients, VTE in cancer is more frequently associated with clinical consequences, including recurrent VTE, bleeding, and an increase in the risk of death. Low-molecular-weight heparins (LMWHs) are commonly recommended for the prevention and treatment of VTE in cancer patients because of their favorable risk-to-benefit profile. Indeed, compared with vitamin K antagonists, LMWHs are characterized by a reduced need for coagulation monitoring, few major bleeding episodes, and once-daily dosing, which make these drugs more suitable in the cancer setting. Guidelines have been published recently with the aim to improve the clinical outcomes in cancer patients at risk of VTE and its complications. Coagulation activation in cancer may have a role not only in thrombosis but also in tumor growth and dissemination. Hence, inhibition of fibrin formation has been considered a possible tool against the progression of malignant disease. Clinical studies show that anticoagulant drugs may have a beneficial effect on survival in cancer patients, with a major role for LMWHs. Recently a number of prospective randomized clinical trials to test LMWHs to improve cancer survival as a primary endpoint in cancer patients have been conducted. Although the results are controversial, the interest in this research area remains high.

Keywords: venous thromboembolism, VTE, LMWH

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study

Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, Montori VM

Patient Related Outcome Measures 2012, 3:39-49

Published Date: 24 August 2012

Rasch analysis of the Dutch version of the Oxford elbow score

de Haan J, Schep NW, Tuinebreijer WE, Patka P, den Hartog D

Patient Related Outcome Measures 2011, 2:145-149

Published Date: 2 August 2011

Application of PIP data in health economic models for market access

Nadine van Dongen, Mark JC Nuijten

Patient Intelligence 2010, 2:53-58

Published Date: 24 November 2010

Health-related restrictions of choices and choosing: implications for quality of life and clinical interventions

Barry J Gurland, Huai Cheng, Mathew S Maurer

Patient Related Outcome Measures 2010, 1:73-80

Published Date: 11 August 2010

Oral versus topical carbonic anhydrase inhibitors in ocular hypertension after scleral tunnel cataract surgery

Abdulmoghni Al-Barrag, Motaher Al-Shaer, Nabil Al-Matary, Mahfoud Bamashmous

Clinical Ophthalmology 2009, 3:357-362

Published Date: 11 June 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Candida albicans keratitis modified by steroid application

Kaoru Araki-Sasaki, Hiroko Sonoyama, Tsutomu Kawasaki, Nariyasu Kazama, Hidenao Ideta, et al.

Clinical Ophthalmology 2009, 3:231-233

Published Date: 26 February 2009